Developer docs
API playgroundTry for free, no card

Search company profiles

Synarc

Full company profile

uuid0008luy

Namestring
Synarc
Websiteurl
bioclinica.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Synarc Inc. was founded in 1998 as a Maynard, Massachusetts-based provider of medical imaging and molecular marker services for clinical trials, serving pharmaceutical and biotechnology sponsors running imaging-intensive studies. Its core offering combined centralized imaging core lab capabilities and biomarker assays with operational workflows tailored to multi-site clinical trials. The firm pursued a roll-up strategy, including the July 2004 acquisition of IoDP, and was capitalized via venture funding — a $10.2 million round in March 2004 (led by SV Health Investors and U.S. Venture Partners) and a $5 million round in April 2008. Co-founder Harry K. Genant anchored the scientific leadership as Emeritus Chairman and Senior Consultant.

Synarc subsequently became part of BioClinica (per firmographic website linkage to bioclinica.com) and, through subsequent consolidation, contributed the medical imaging and molecular marker franchise to the broader clinical trial endpoint platform operated today as Clario. In its successor configuration the platform spans five endpoint categories — cardiac safety, eCOA, medical imaging, precision motion (Opal wearable), and respiratory — supported by a cloud-native architecture, connected devices, and AI-enabled tools (including Image Redact AI), deployed across 100+ countries. Revenue mechanics operate through enterprise service contracts with pharma sponsors, biotechs, and CROs at quote-based pricing tied to trial scope, therapeutic area, and phase, with recurring platform/device components supplementing project-based services. In October 2025 Thermo Fisher Scientific completed its acquisition of Clario Holdings Inc., folding Synarc's legacy capabilities into a broader laboratory and manufacturing services franchise.

Short descriptiontext

Synarc provides centralized medical imaging and molecular marker services for clinical trials, serving pharmaceutical sponsors, biotechs, and CROs running imaging-intensive drug development studies. Founded 1998.

Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical trial imaging, molecular marker services, biomarker analysis, medical imaging core lab, clinical research services
Industry3 codes
1Central Laboratory & Clinical Trial Testing CROs
CodeHLAGAAAEPrimaryYes
2Clinical Research & Trial Central Laboratories
CodeHLAFAMALPrimaryNo
3Proteomics & Biomarker Analytical Testing
CodeHLAGADAGPrimaryNo
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Imaging Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Endpoint Technology Services
TypeSubscription Recurring
Description

Provides proprietary endpoint technologies and evidence generation solutions to pharma sponsors, biotechs, and CROs conducting clinical trials. Revenue is generated through service contracts for cardiac safety, eCOA, medical imaging, precision motion, and respiratory solutions across all trial phases. The model combines technology platform fees, device/services pricing, and scientific/regulatory consulting services.

clario.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Synarc Inc. is a provider of medical imaging and molecular marker services that supports pharmaceutical, biotechnology, and medical device sponsors running clinical trials. The company delivers centralized imaging core lab capabilities and biomarker/molecular marker analyses used as endpoints or surrogate endpoints in clinical studies. Its services are designed to generate quantitative, reproducible imaging and biomarker data to support drug development, regulatory submissions, and clinical research across therapeutic areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 70% of FDA and EMA new drug approvals since 2015 involved Clario's technology
+3 more records
Product overview1 text field

Clario is a clinical trial endpoint technology company providing the most comprehensive evidence generation platform in the industry. The company offers a unified platform combining validated clinical trial management software, connected medical devices, and AI solutions. Core product categories include: Cardiac Solutions (arrhythmia analysis, blood pressure, ECG monitoring for Phase I-IV trials), eCOA (electronic clinical outcome assessments with specialized solutions like eCOA Swift for early-phase oncology and eCOA Rapid Start for faster trial setup), Medical Imaging (core lab services with AI-powered Image Redact AI), Precision Motion (Opal wearable sensor technology for mobility endpoints), Respiratory Solutions (spirometry, home testing, lung sound assessment), Trial Enablement (eligibility management, analytics, document management), and Clinical Adjudication. The platform supports site-based, hybrid, and decentralized clinical trials across 100+ countries with 24/7 support.

Product and service2 records
1Medical Imaging Services for Clinical Trials
CategoryClinical Trial Imaging Services
2Molecular Marker Services
CategoryClinical Trial Laboratory Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1IQVIA
TypeDirect peer
Description

IQVIA is the largest global CRO with extensive clinical trial endpoint technology, eCOA, and imaging capabilities. It is a direct competitor to the Synarc/Clario endpoint services business across pharma, biotech, and CRO customer segments.

2ICON plc
TypeDirect peer
Description

ICON, including PRA Health Sciences, offers a broad range of clinical research services including imaging, eCOA, and bioanalytical labs. It serves the same pharma/biotech client base as Synarc with overlapping endpoint service capabilities.

3Parexel International
TypeDirect peer
Description

Parexel is a global CRO offering clinical trial technology, imaging, and biomarker services with comparable CRO-and-biotech client mix to Synarc's clinical trial endpoint services.

4Calyx (formerly Parexel informatics)
TypeEmerging player
Description

Calyx provides eCOA, imaging, and clinical trial technology solutions, with comparable endpoint technology focus and overlapping customer base in pharma and biotech sponsors.

5Medpace
TypeDirect peer
Description

Medpace is a mid-size clinical CRO with growing imaging, central lab, and eCOA capabilities serving biotech and mid-tier pharma, overlapping with Synarc's clinical trial endpoint service model for biotechs.

6Charles River Laboratories
TypeBroad incumbent
Description

Charles River provides preclinical and clinical lab services including biomarker and central lab capabilities for clinical trials, comparable in central laboratory testing and biomarker analytical services to Synarc's molecular marker offerings.

7BioTelemetry (Philips)
TypeDirect peer
Description

BioTelemetry, now part of Philips, is a leader in cardiac safety services for clinical trials and a direct peer in the cardiac solutions and ECG monitoring business Synarc addresses.

8Signant Health
TypeEmerging player
Description

Signant Health is a clinical technology provider specializing in eCOA, ePRO, and patient-centric clinical trial solutions, competing directly in the digital clinical outcome assessment space that Clario's Synarc unit addresses.

9Worldwide Clinical Trials
TypeDirect peer
Description

Worldwide Clinical Trials is a midsize CRO with scientific and endpoint expertise across multiple therapeutic areas, overlapping with Synarc's clinical research services and central laboratory model.

10Labcorp Drug Development
TypeDirect peer
Description

Labcorp (including Covance and early development/Fortrea spin) provides central laboratory and clinical trial services spanning biomarker testing, imaging, and bioanalytical work, directly competing with Synarc's central lab and clinical trial testing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synarc

Clinical Trial Imaging Servicesbioclinica.com

Synarc provides centralized medical imaging and molecular marker services for clinical trials, serving pharmaceutical sponsors, biotechs, and CROs running imaging-intensive drug development studies. Founded 1998.

What Synarc does

Synarc Inc. was founded in 1998 as a Maynard, Massachusetts-based provider of medical imaging and molecular marker services for clinical trials, serving pharmaceutical and biotechnology sponsors running imaging-intensive studies. Its core offering combined centralized imaging core lab capabilities and biomarker assays with operational workflows tailored to multi-site clinical trials. The firm pursued a roll-up strategy, including the July 2004 acquisition of IoDP, and was capitalized via venture funding — a $10.2 million round in March 2004 (led by SV Health Investors and U.S. Venture Partners) and a $5 million round in April 2008. Co-founder Harry K. Genant anchored the scientific leadership as Emeritus Chairman and Senior Consultant.

Synarc subsequently became part of BioClinica (per firmographic website linkage to bioclinica.com) and, through subsequent consolidation, contributed the medical imaging and molecular marker franchise to the broader clinical trial endpoint platform operated today as Clario. In its successor configuration the platform spans five endpoint categories — cardiac safety, eCOA, medical imaging, precision motion (Opal wearable), and respiratory — supported by a cloud-native architecture, connected devices, and AI-enabled tools (including Image Redact AI), deployed across 100+ countries. Revenue mechanics operate through enterprise service contracts with pharma sponsors, biotechs, and CROs at quote-based pricing tied to trial scope, therapeutic area, and phase, with recurring platform/device components supplementing project-based services. In October 2025 Thermo Fisher Scientific completed its acquisition of Clario Holdings Inc., folding Synarc's legacy capabilities into a broader laboratory and manufacturing services franchise.

Synarc firmographics

Firmographics
Name
Synarc
Website
https://bioclinica.com
Company type
Private
Founded year
1998
Headcount range
5,001–10,000 employees
Short description
Synarc provides centralized medical imaging and molecular marker services for clinical trials, serving pharmaceutical sponsors, biotechs, and CROs running imaging-intensive drug development studies. Founded 1998.
Ownership category
akta.pro rank

Synarc industry classification

Industry
Product category
Clinical Trial Imaging Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
akta.pro secondary industries
Clinical Research & Trial Central Laboratories (HLAFAMAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

  • Clinical trial imaging
  • Molecular marker services
  • Biomarker analysis
  • Medical imaging core lab
  • Clinical research services

Where Synarc is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Synarc business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Clinical Trial Endpoint Technology Services: Provides proprietary endpoint technologies and evidence generation solutions to pharma sponsors, biotechs, and CROs conducting clinical trials. Revenue is generated through service contracts for cardiac safety, eCOA, medical imaging, precision motion, and respiratory solutions across all trial phases. The model combines technology platform fees, device/services pricing, and scientific/regulatory consulting services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Synarc product offering

Product offering

Core offering

Synarc Inc. is a provider of medical imaging and molecular marker services that supports pharmaceutical, biotechnology, and medical device sponsors running clinical trials. The company delivers centralized imaging core lab capabilities and biomarker/molecular marker analyses used as endpoints or surrogate endpoints in clinical studies. Its services are designed to generate quantitative, reproducible imaging and biomarker data to support drug development, regulatory submissions, and clinical research across therapeutic areas.

Product overview

Clario is a clinical trial endpoint technology company providing the most comprehensive evidence generation platform in the industry. The company offers a unified platform combining validated clinical trial management software, connected medical devices, and AI solutions. Core product categories include: Cardiac Solutions (arrhythmia analysis, blood pressure, ECG monitoring for Phase I-IV trials), eCOA (electronic clinical outcome assessments with specialized solutions like eCOA Swift for early-phase oncology and eCOA Rapid Start for faster trial setup), Medical Imaging (core lab services with AI-powered Image Redact AI), Precision Motion (Opal wearable sensor technology for mobility endpoints), Respiratory Solutions (spirometry, home testing, lung sound assessment), Trial Enablement (eligibility management, analytics, document management), and Clinical Adjudication. The platform supports site-based, hybrid, and decentralized clinical trials across 100+ countries with 24/7 support.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Imaging Services for Clinical Trials
  • Molecular Marker Services

Quantifiable outcome

  • 70% of FDA and EMA new drug approvals since 2015 involved Clario's technology
  • +3 more outcomes

Companies that use Synarc

Customer profile

Segments3 records

Ideal customer profiles1 record

Synarc technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Synarc partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Synarc competitors and assessment

Company assessment

Direct peers

  • IQVIA: IQVIA is the largest global CRO with extensive clinical trial endpoint technology, eCOA, and imaging capabilities. It is a direct competitor to the Synarc/Clario endpoint services business across pharma, biotech, and CRO customer segments.
  • ICON plc: ICON, including PRA Health Sciences, offers a broad range of clinical research services including imaging, eCOA, and bioanalytical labs. It serves the same pharma/biotech client base as Synarc with overlapping endpoint service capabilities.
  • Parexel International: Parexel is a global CRO offering clinical trial technology, imaging, and biomarker services with comparable CRO-and-biotech client mix to Synarc's clinical trial endpoint services.
  • Medpace: Medpace is a mid-size clinical CRO with growing imaging, central lab, and eCOA capabilities serving biotech and mid-tier pharma, overlapping with Synarc's clinical trial endpoint service model for biotechs.
  • BioTelemetry (Philips): BioTelemetry, now part of Philips, is a leader in cardiac safety services for clinical trials and a direct peer in the cardiac solutions and ECG monitoring business Synarc addresses.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a midsize CRO with scientific and endpoint expertise across multiple therapeutic areas, overlapping with Synarc's clinical research services and central laboratory model.
  • Labcorp Drug Development: Labcorp (including Covance and early development/Fortrea spin) provides central laboratory and clinical trial services spanning biomarker testing, imaging, and bioanalytical work, directly competing with Synarc's central lab and clinical trial testing model.

Emerging players

  • Calyx (formerly Parexel informatics): Calyx provides eCOA, imaging, and clinical trial technology solutions, with comparable endpoint technology focus and overlapping customer base in pharma and biotech sponsors.
  • Signant Health: Signant Health is a clinical technology provider specializing in eCOA, ePRO, and patient-centric clinical trial solutions, competing directly in the digital clinical outcome assessment space that Clario's Synarc unit addresses.

Broad incumbents

  • Charles River Laboratories: Charles River provides preclinical and clinical lab services including biomarker and central lab capabilities for clinical trials, comparable in central laboratory testing and biomarker analytical services to Synarc's molecular marker offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Synarc social profiles

Digital presence

Synarc compliance and trust

Trust signal

Compliance3 records

Synarc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synarc leadership team

Management profile

Number of profiles

Profiles1 record

Synarc funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synarc M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synarc

What does Synarc do?

Synarc Inc. is a provider of medical imaging and molecular marker services that supports pharmaceutical, biotechnology, and medical device sponsors running clinical trials. The company delivers centralized imaging core lab capabilities and biomarker/molecular marker analyses used as endpoints or surrogate endpoints in clinical studies. Its services are designed to generate quantitative, reproducible imaging and biomarker data to support drug development, regulatory submissions, and clinical research across therapeutic areas.

When was Synarc founded?

Synarc was founded in 1998. It employs 5,001 to 10,000 people.

Where is Synarc based?

Synarc is headquartered in San Francisco, United States, in the North America region.

How does Synarc make money?

One revenue line is on record: clinical Trial Endpoint Technology Services.

Who are Synarc's main competitors?

Direct peers on record are IQVIA, ICON plc, Parexel International, Medpace, BioTelemetry (Philips), Worldwide Clinical Trials and Labcorp Drug Development. Emerging players are Calyx (formerly Parexel informatics) and Signant Health. Charles River Laboratories is listed as a broad incumbent.

Does Synarc have an API?

No public API is recorded for Synarc.

What industry is Synarc in?

Synarc's product category is Clinical Trial Imaging Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 5417 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales